Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year.
Summary
SB 1528 expands Oregon’s prescription drug price-reporting law by requiring drug manufacturers to disclose more information about patient assistance programs they offer or fund for consumers in the state. Under the bill, manufacturers that already must report on certain high-priced drugs with significant annual price increases would also have to report, each year, the number of Oregon consumers using each assistance program, the total value of coupons, discounts, copay assistance, or other cost reductions, the number of qualifying refills, the duration of the program if it expires, and the eligibility criteria and verification process. The bill also retains existing reporting requirements on drug price increases, pricing history, costs, revenues, profits, and new drug introductions.
Impact
The bill amends ORS 646A.689, which is part of Oregon’s drug price transparency framework, and makes the new patient assistance program reporting requirements operative on January 1, 2028. It would expand the information the Oregon Health Authority receives, posts, and can use to monitor prescription drug pricing and manufacturer assistance programs, while preserving the department’s authority to request supporting documentation and impose civil penalties for noncompliance. The bill also continues to require annual reporting to legislative health committees and to the Prescription Drug Affordability Board, potentially affecting manufacturers, consumers, state health programs, and public and private insurance purchasers.
Sentiment
The available voting history suggests the bill had meaningful but not overwhelming support. It passed the Senate committee on a 3-2 do pass with amendments vote and later cleared Senate third reading by a 17-10 vote, indicating a partisan or policy split rather than broad consensus. No committee transcript is available here, but the overall posture of the bill is consistent with a transparency-focused health care measure that drew support from members favoring drug cost oversight and some opposition from those concerned about regulatory burden or disclosure requirements.
Contention
The main point of contention appears to be the scope of manufacturer reporting, especially the requirement to disclose details about all patient assistance programs offered or funded for Oregon consumers. Supporters likely view the added reporting as necessary to understand how assistance programs interact with drug pricing and consumer out-of-pocket costs, while opponents may see it as an expanded compliance burden and a potential exposure of sensitive business information. The bill’s public posting provisions and trade secret carve-out also suggest tension between transparency and confidentiality, particularly for manufacturers concerned about proprietary pricing and program data.